Call us : +27 31-563 0419
Mail us : info@scalenesouthafrica.com

Haemoseis 256

The Haemoseis-256® is a non-invasive cardiovascular diagnostic device that provides a comprehensive assessment (3D Cartography with 3D Vasculography) of an individual’s cardiopulmonary and renal physiology, with accuracy, ease of use, and cost efficiency

haemoseis-256-3d-vasculography-system-500x500.png

Haemoseis 3D-Vasculography is a revolutionary, non-invasive technology for early identification and management of life threatening cardiovascular diseases. In less than 5 minutes, the test provides a detailed analysis of cardiovascular and pulmonary haemodynamics, electrophysiology and other co-morbidities, providing more than sixty vital cardiovascular parameters such as critical regional and myocardial blood flow functions to identify and characterize electro-haemodynamic patterns which are consistent with coronary artery disease (CAD) and other cardiac disease states. With such a vital haemodynamic profile of the Cardiovascular & renal flow system, the Haemoseis 256 brings new and powerful information to the out-patient clinic, emergency rooms, intensive coronary, neonatal or pediatric care units, cath labs and operating rooms. The test provides unique details of minute deviations in flow patterns, invaluable for accurate monitoring of cardiac functions, in one simple test.

Features & Benefits

  • Has US FDA ‘Non-Significant Risk’ designation

  • Non-invasive comprehensive 5-minute Cardiovascular Diagnostics in 256 heart beats

  • Cardiotoxicity monitoring for long-term risk assessment

  • Complete profile of Cardio-pulmonary Dynamics

  • Other related indications (Diabetes, Hypertension etc.) detected early

  • Screening of high-risk populations in affected communities

  • Preventing sudden cardiac death in symptom-less young adults/athletes

  • Monitoring High-risk pregnancies for pre-eclampsia

  • Mexican COFEPRIS approved

  • Monitoring patients in PICU, ICU, ICCU, ambulatory services

  • Legacy devices are CE certified

  • Retained as Trade Secret for IP protection

  • Multiple installations in Asia & Europe

  • Limits the plethora of tests performed otherwise

  • Allows affordable out-of-pocket life-saving diagnosis

  • Saves downtime on jobs, improves throughput

  • Attractive to medical centers & insurance providers

Partial (non-exhaustive) list of Parameters with 3D Vasculography

PHYSIOLOGICAL PARAMETERS

  • Stroke volume - ml

  • Stroke index - ml / m²

  • Cardiac output - l / min

  • Systemic vascular resistance - dyne.sec.cm^-5

  • Mean arterial blood pressure - mmHg

  • End systolic volume beat to beat

  • End diastolic volume beat to beat

  • Global myocardial blood flow - ml / min / 100gm

  • Regional myocardial blood flow - ml / min / 100gm

  • Total coronary resistance - dyne.sec.cm^-5

  • Mean coronary perfusion pressure - mmHg

  • Systolic and diastolic time intervals - milliseconds

  • Pulmonary air retention - %

  • Pulmonary fluid retention - %

  • Pulmonary capillary pressure - mmHg

  • Pulmonary vascular resistance - dyne.sec.cm^-5

  • Renal glomerular filtration rate (GFR) - ml / min

  • Urine output - ml / min

FUNCTIONAL PARAMETERS

  • Complete real time cardiac cycle

  • Left ventricular ejection fraction LVEF beat to beat

  • Left ventricle regurgitant fraction

  • Left cardiac work

  • Maximal oxygen consumption

  • Myocardial oxygen demand, supply & reserve

  • Coronary flow reserve

  • Global myocardial flow deficiency index

  • Collateral flow index

  • Global cardiac efficiency

  • Thrombus formation factor

  • Adrenergic analysis

  • Total myocardial burden

  • Pliability of mitral and aortic valve

  • Body fat mass estimate - Kgs

  • Basal metabolic rate - Kcal / hr / m²

Clinical Application

  • Can be used effectively before, during and after procedures like External Counter Pulsation (ECP) or Intra-aortic Balloon Pump (IABP), where measurement of coronary perfusion pressure, coronary blood fow, valvular pliability is important.

  • Establishing arrhythmogenic focus of Early and Delayed after depolarisation (EAD and DAD) in CAD and myocardial diseases and proneness to sudden cardiac death syndrome (SCDS).

  • Measurement of arterial elasticity under-pinning endothelial function and progression of the atherosclerosis process in diabetic and hypertensive patients.

  • Understanding underlying causes of chest pain in the absence of CAD and early detection in asymptomatic subjects.

  • Determination of actual working point of the heart and establishing working capacity in post-infarction recovery.

  • Establishing ANS activity in patients with diabetic neuropathy and controlling thrombogenicity.

  • Forecast & signal myocardial ischemia, prior to the development of angina.

  • Follow up for neonates where invasive techniques are impossible.

  • Reliable detection of CAD and its severity.

  • Measurement of ionotropic effects.

  • Measurement of ventricular elasticity and diastolic stretch in cardiac hypertrophy analysis.

  • During anesthesia, general narcosis and regional techniques.

  • Pre-operative assessment of cardio-pulmonary fitness.

  • In critical care medicine for monitoring vital functions non-invasively and understanding drug action.

  • Optimising AV delay in dual chamber pace makers.

  • Estimation of GFR, renal fraction, urine output and fluid overload during dialysis, plasmapheresis.

  • Early detection of pulmonary oedema, before the development of clinical symptoms.

  • Early detection of COPD, its progression and effect of treatment.

  • Aids in decision making while choosing the line of management.

  • Follow up of Coronary Artery Bypass Graft (CABG) and Percutaneous Transluminal Coronary Angioplasty (PTCA) patients.

  • Establishment of functional effectiveness of drugs and medicines.

  • Establishment of pliability of mitral and aortic valves in valvular dysfunction.

Please visit the Resource tab for more detailed information about Haemoseis-256, including; journal articles, brochures, patents, and media